| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC10924 | BMS986202 Featured | BMS-986202 is a clinical Tyk2 inhibitor that binds to Tyk2 JH2 with IC50 of 0.19 nM and shows remarkably selectivity over other kinases including Jak family members. |
|
| DC10131 | BMS-986205(Linrodostat) Featured | BMS-986205 is an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic activity, alone and in combination with nivolumab in advanced cancers in a phase 1/2a trial |
|
| DC22036 | BMT-046091 | BMT-046091 (BMT046091) is a potent and selective AAK1 inhibitor with IC50 of 2.8 nM. |
|
| DC11989 | BMT-090605 | BMT-090605 (BMT 090605, BMT090605) is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50 0.6 nM. |
|
| DC9937 | BMT-145027 | BMT-145027 is a potent mGluR5 PAM with no inherent mGluR5 agonist activity. |
|
| DC23998 | BMX-IN-1 Featured | BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity. |
|
| DC7377 | BMY 7378 Featured | BMY 7378 is a multi-targeted inhibitor of α2C-adrenoceptor and α1D-adrenoceptor with pKi of 6.54 and 8.2, respectively, and acts as a mixed agonist and antagonist for 5-HT1A receptor with pKi of 8.3. |
|
| DC23754 | BNC-1 | BNC-1 is a small molecule modulator of Amyloid pathology by promoting phosphorylation and activation of Elk-1, a transcriptional repressor of presenilin-1 but not presenilin-2. |
|
| DC7773 | BNC-105 Featured | BNC105 is a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. |
|
| DC23262 | BNM-III-170 | BNM-III-170 is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo. |
|
| DC23243 | BNM-III-170 trifluoroacetate | BNM-III-170 TFA salt is a small-molecule CD4-mimetic compound that enhances vaccine efficacy against HIV-1 challenge in vivo. |
|
| DC20823 | BNS-22 | BNS-22 is a small-molecule inhibitor of DNA topoisomerase II, inhibits kinetoplast DNA decatenation that is mediated by human TOP2α and TOP2β in vitro with IC50 of 2.8 and 0.42 uM, respectively. |
|
| DC22037 | Bobcat339 Featured | Bobcat339 (Bobcat 339) is a novel cytosine-based TET enzyme inhibitor with IC50 of 33 uM (TET1) and 73 uM (TET2), but not DNMT3a, does not inhibit the DNA methyltransferase DNMT3a. |
|
| DC23218 | BOC-D-FMK Featured | BOC-D-FMK is a cell-permeable, irreversible, broad spectrum caspase inhibitor, inhibits apoptosis stimulated by TNF-α with IC50 of 39 uM. |
|
| DC5077 | Boceprevir(EBP 520; SCH 503034 ) Featured | Boceprevir(EBP 520; SCH 503034 ) is useful for Anti HCV. |
|
| DC20034 | Boc-MLF TFA | Boc-MLF (TFA) is a peptide, used as a specific formyl peptide receptor (FPR) antagonist, also inhibits the signaling through formyl peptide receptor like 1 (FPRL1) at higher concentrations. |
|
| DC8073 | Bohemine Featured | Bohemine is a synthetic, cell-permeable, cyclin-dependent kinase inhibitor. |
|
| DC9547 | Boldenone Undecylenate | Boldenone undecylenate(Equipoise) is a synthetic steroid which has a similar effect as the natural steroid testosterone; it is frequently used in veterinary medicine, though it is also used in humans. |
|
| DC1027 | Bortezomib (Velcade,MG-341,PS-341) Featured | Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM. |
|
| DC21869 | Borussertib Featured | Borussertib is a potent, first-in-class, covalent-allosteric AKT inhibitor. |
|
| DC12405 | BOS172722 Featured | BOS172722 (BOS-172722) is a potent, selective MPS1 kinase inhibitor with biochemical IC50 of 11 nM, 100-fold selectivity over CDK2. |
|
| DC9437 | Bosentan | Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. |
|
| DCAPI1483 | Bosentan Hydrate | Bosentan is an endothelin (ET) receptors antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively. |
|
| DC5164 | Bosutinib (SKI-606) Featured | Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. |
|
| DC23896 | Box5 | Box5 is a Wnt5a-derived N-butyloxycarbonyl hexapeptide (t-Boc-Met-Asp-Gly-Cys-Glu-Leu), acts as an Wnt5a antagonist. |
|
| DC8040 | STAT3 Inhibitor XVIII, BP-1-102 Featured | BP-1-102 is a potent, orally bioavailable and selective STAT3 inhibitor. |
|
| DC8883 | BP897 Featured | BP897 is a partially selective D3 dopamine receptor agonist. |
|
| DC20322 | BPIPP | BPIPP is an inhibitor of GC-C (guanylyl cyclase type C) that inhibits stimulation of guanylyl cyclase and adenylyl cyclase, suppresses cGMP accumulation in a variety of cell lines (IC50=3.4-11.2 uM). |
|
| DC11499 | BPK-29 | BPK-29 is a covalent, specific small molecule that disrupts NR0B1 protein complexes and impairs the anchorage-independent growth of KEAP1-mutant cancer cells. |
|
| DC12608 | BPN14770 Featured | BPN14770 (BPN-14770) is an allosteric inhibitor of phosphodiesterase 4D (PDE4D) with IC50 of 7.8 and 7.4 nM for human PDE4D7 and PDE4D3 respectively, displays 16-fold less potent against monomeric form of PDE4D lacking the UCR1 dimerization domain (PDE4D2 |
|
